Alzheimer's disease, apolipoprotein E and hormone replacement therapy

Maturitas

Volumn 94, Issue , 2016, Pages 98-105

  Depypere, H ^a   Vierin, A ^a   Weyers, S ^a   Sieben, A ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Alzheimer's disease; APO lipoprotein; Hormone therapy

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; ESTROGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; GENETIC RISK; GENOTYPE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; META ANALYSIS (TOPIC); OVARIECTOMY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ESTROGEN THERAPY; FEMALE; GENETICS; INCIDENCE; PREVALENCE;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; INCIDENCE; MENOPAUSE; NEUROPROTECTIVE AGENTS; PREVALENCE;

EID: 84991721645     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2016.09.009     Document Type: Review

References (91)

1. [1] Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., Ferri, C.P., The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer's Dement.: J. Alzheimer's Assoc. 9:1 (2013), 63–75 (e2).
2. [2] Sosa-Ortiz, A.L., Acosta-Castillo, I., Prince, M.J., Epidemiology of dementias and Alzheimer's disease. Arch. Med. Res. 43:8 (2012), 600–608.
3. [3] Wu, Y.T., Fratiglioni, L., Matthews, F.E., Lobo, A., Breteler, M.M., Skoog, I., et al. Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurol. 15:1 (2016), 116–124.
4. [4] Wu, Y.T., Matthews, F.E., Brayne, C., Dementia: time trends and policy responses. Maturitas 79:2 (2014), 191–195.
5. [5] Alzheimer's, A., 2015 Alzheimer's disease facts and figures. Alzheimer's Dement.: J. Alzheimer's Assoc. 11:3 (2015), 332–384.
6. [6] Andersen, K., Launer, L.J., Dewey, M.E., Letenneur, L., Ott, A., Copeland, J.R., et al. Gender differences in the incidence of AD and vascular dementia: the EURODEM studies: EURODEM incidence research group. Neurology 53:9 (1999), 1992–1997.
7. [7] Fratiglioni, L., Viitanen, M., von Strauss, E., Tontodonati, V., Herlitz, A., Winblad, B., Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project Stockholm. Neurology 48:1 (1997), 132–138.
8. [8] Miech, R.A., Breitner, J.C., Zandi, P.P., Khachaturian, A.S., Anthony, J.C., Mayer, L., Incidence of AD may decline in the early 90 s for men, later for women: the Cache County study. Neurology 58:2 (2002), 209–218.
9. [9] Kawas, C., Resnick, S., Morrison, A., Brookmeyer, R., Corrada, M., Zonderman, A., et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 48:6 (1997), 1517–1521.
10. [10] Tang, M.X., Jacobs, D., Stern, Y., Marder, K., Schofield, P., Gurland, B., et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348:9025 (1996), 429–432.
11. [11] Zandi, P.P., Carlson, M.C., Plassman, B.L., Welsh-Bohmer, K.A., Mayer, L.S., Steffens, D.C., et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 288:17 (2002), 2123–2129.
12. [12] MacLennan, A.H., Henderson, V.W., Paine, B.J., Mathias, J., Ramsay, E.N., Ryan, P., et al. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause 13:1 (2006), 28–36.
13. [13] Phung, T.K., Waltoft, B.L., Laursen, T.M., Settnes, A., Kessing, L.V., Mortensen, P.B., et al. Hysterectomy, oophorectomy and risk of dementia: a nationwide historical cohort study. Dement. Geriatr. Cogn. Disord. 30:1 (2010), 43–50.
14. [14] Rocca, W.A., Bower, J.H., Maraganore, D.M., Ahlskog, J.E., Grossardt, B.R., de Andrade, M., et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69:11 (2007), 1074–1083.
15. [15] Mielke, M.M., Vemuri, P., Rocca, W.A., Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin. Epidemiol. 6 (2014), 37–48.
16. [16] Liu, C.C., Kanekiyo, T., Xu, H., Bu, G., Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9:2 (2013), 106–118.
17. [17] Rocca, W.A., Mielke, M.M., Vemuri, P., Miller, V.M., Sex and gender differences in the causes of dementia: a narrative review. Maturitas 79:2 (2014), 196–201.
18. [18] Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82:4 (1991), 239–259.
19. [19] Montine, T.J., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Dickson, D.W., et al. National Institute on Aging-Alzheimer's association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 123:1 (2012), 1–11.
20. [20] Thal, D.R., Rub, U., Orantes, M., Braak, H., Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:12 (2002), 1791–1800.
21. [21] Lane-Donovan, C., Philips, G.T., Herz, J., More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration. Neuron 83:4 (2014), 771–787.
22. [22] Bu, G., Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10:5 (2009), 333–344.
23. [23] Hauser, P.S., Ryan, R.O., Impact of apolipoprotein E on Alzheimer's disease. Curr. Alzheimer Res. 10:8 (2013), 809–817.
24. [24] Klein, W.L., Krafft, G.A., Finch, C.E., Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 24:4 (2001), 219–224.
25. [25] Hardy, J.A., Higgins, G.A., Alzheimer's disease: the amyloid cascade hypothesis. Science 256:5054 (1992), 184–185.
26. [26] Spires-Jones, T.L., Hyman, B.T., The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 82:4 (2014), 756–771.
27. [27] Maccioni, R.B., Munoz, J.P., Barbeito, L., The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch. Med. Res. 32:5 (2001), 367–381.
28. [28] Guo, J.L., Lee, V.M., Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem. 286:17 (2011), 15317–15331.
29. [29] Aizenstein, H.J., Nebes, R.D., Saxton, J.A., Price, J.C., Mathis, C.A., Tsopelas, N.D., et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65:11 (2008), 1509–1517.
30. [30] Villeneuve, S., Wirth, M., La Joie, R., Are AD-typical regions the convergence point of multiple pathologies?. Front. Aging Neurosci., 7, 2015, 42.
31. [31] Xing, Y., Jia, J.P., Ji, X.J., Tian, T., Estrogen associated gene polymorphisms and their interactions in the progress of Alzheimer's disease. Prog. Neurobiol. 111 (2013), 53–74.
32. [32] Rader, D.J., Hoeg, J.M., Brewer, H.B. Jr., Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann. Intern. Med. 120:12 (1994), 1012–1025.
33. [33] Hauser, P.S., Narayanaswami, V., Ryan, R.O., Apolipoprotein E: from lipid transport to neurobiology. Prog. Lipid Res. 50:1 (2011), 62–74.
34. [34] Yu, J.T., Tan, L., Hardy, J., Apolipoprotein E in Alzheimer's disease: an update. Annu. Rev. Neurosci. 37 (2014), 79–100.
35. [35] Farrer, L.A., Cupples, L.A., Haines, J.L., Hyman, B., Kukull, W.A., Mayeux, R., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278:16 (1997), 1349–1356.
36. [36] Ringman, J.M., Coppola, G., New genes and new insights from old genes: update on Alzheimer disease. Continuum 19:2 Dementia (2013), 358–371.
37. [37] Ward, A., Crean, S., Mercaldi, C.J., Collins, J.M., Boyd, D., Cook, M.N., et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. Neuroepidemiology 38:1 (2012), 1–17.
38. [38] Ryan, J., Scali, J., Carriere, I., Amieva, H., Rouaud, O., Berr, C., et al. Impact of a premature menopause on cognitive function in later life. BJOG 121:13 (2014), 1729–1739.
39. [39] Fox, M., Berzuini, C., Knapp, L.A., Cumulative estrogen exposure, number of menstrual cycles, and Alzheimer's risk in a cohort of British women. Psychoneuroendocrinology 38:12 (2013), 2973–2982.
40. [40] Bove, R., Secor, E., Chibnik, L.B., Barnes, L.L., Schneider, J.A., Bennett, D.A., et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology 82:3 (2014), 222–229.
41. [41] Rocca, W.A., Grossardt, B.R., Maraganore, D.M., The long-term effects of oophorectomy on cognitive and motor aging are age dependent. Neurodegener. Dis. 5:3–4 (2008), 257–260.
42. [42] Farrag, A.K., Khedr, E.M., Abdel-Aleem, H., Rageh, T.A., Effect of surgical menopause on cognitive functions. Dement. Geriatr. Cogn. Disord. 13:3 (2002), 193–198.
43. [43] Imtiaz, B., Tuppurainen, M., Tiihonen, M., Kivipelto, M., Soininen, H., Hartikainen, S., et al. Oophorectomy, hysterectomy, and risk of Alzheimer's disease: a nationwide case-control study. J. Alzheimer's Dis.: JAD 42:2 (2014), 575–581.
44. [44] Rocca, W.A., Grossardt, B.R., Shuster, L.T., Stewart, E.A., Hysterectomy, oophorectomy, estrogen, and the risk of dementia. Neurodegener. Dis. 10:1–4 (2012), 175–178.
45. [45] Murphy, D.D., Segal, M., Regulation of dendritic spine density in cultured rat hippocampal neurons by steroid hormones. J. Neurosci. 16:13 (1996), 4059–4068.
46. [46] Woolley, C.S., McEwen, B.S., Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J. Neurosci. 12:7 (1992), 2549–2554.
47. [47] Stampfer, M.J., Cardiovascular disease and Alzheimer's disease: common links. J. Intern. Med. 260:3 (2006), 211–223.
48. [48] Ayres, S., Tang, M., Subbiah, M.T., Estradiol-17beta as an antioxidant: some distinct features when compared with common fat-soluble antioxidants. J. Lab. Clin. Med. 128:4 (1996), 367–375.
49. [49] Romer, W., Oettel, M., Droescher, P., Schwarz, S., Novel scavestrogens and their radical scavenging effects, iron-chelating, and total antioxidative activities: delta 8,9-dehydro derivatives of 17 alpha-estradiol and 17 beta-estradiol. Steroids 62:3 (1997), 304–310.
50. [50] Gibbs, R.B., Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocr. Rev. 31:2 (2010), 224–253.
51. [51] Gibbs, R.B., Aggarwal, P., Estrogen and basal forebrain cholinergic neurons: implications for brain aging and Alzheimer's disease-related cognitive decline. Horm. Behav. 34:2 (1998), 98–111.
52. [52] Granholm, A.C., Oestrogen and nerve growth factor–neuroprotection and repair in Alzheimer's disease. Expert Opin. Investig. Drugs 9:4 (2000), 685–694.
53. [53] Pan, Y., Anthony, M., Clarkson, T.B., Effect of estradiol and soy phytoestrogens on choline acetyltransferase and nerve growth factor mRNAs in the frontal cortex and hippocampus of female rats. Proc. Soc. Exp. Biol. Med. 221:2 (1999), 118–125.
54. [54] Zhang, Y., Bhavnani, B.R., Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independent mechanisms involving calpain and caspase-3 proteases as well as apoptosis inducing factor (AIF) and this process is inhibited by equine estrogens. BMC Neurosci., 7, 2006, 49.
55. [55] Morinaga, A., Hirohata, M., Ono, K., Yamada, M., Estrogen has anti-amyloidogenic effects on Alzheimer's beta-amyloid fibrils in vitro. Biochem. Biophys. Res. Commun. 359:3 (2007), 697–702.
56. [56] Morinaga, A., Ono, K., Takasaki, J., Ikeda, T., Hirohata, M., Yamada, M., Effects of sex hormones on Alzheimer's disease-associated beta-amyloid oligomer formation in vitro. Expert Neurol. 228:2 (2011), 298–302.
57. [57] Yue, X., Lu, M., Lancaster, T., Cao, P., Honda, S., Staufenbiel, M., et al. Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc. Natl. Acad. Sci. U. S. A. 102:52 (2005), 19198–19203.
58. [58] Merlo, S., Sortino, M.A., Estrogen activates matrix metalloproteinases-2 and -9 to increase beta amyloid degradation. Mol. Cell. Neurosci. 49:4 (2012), 423–429.
59. [59] Yao, M., Nguyen, T.V., Pike, C.J., Estrogen regulates Bcl-w and Bim expression: role in protection against beta-amyloid peptide-induced neuronal death. J. Neurosci. 27:6 (2007), 1422–1433.
60. [60] Alvarez-de-la-Rosa, M., Silva, I., Nilsen, J., Perez, M.M., Garcia-Segura, L.M., Avila, J., et al. Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer's disease. Ann. N. Y. Acad. Sci. 1052 (2005), 210–224.
61. [61] Boardman, H.M., Hartley, L., Eisinga, A., Main, C., Roque i Figuls, M., Bonfill Cosp, X., et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst. Rev., 3, 2015 (CD002229).
62. [62] Baker, L., Meldrum, K.K., Wang, M., Sankula, R., Vanam, R., Raiesdana, A., et al. The role of estrogen in cardiovascular disease. J. Surg. Res. 115:2 (2003), 325–344.
63. [63] LeBlanc, E.S., Janowsky, J., Chan, B.K., Nelson, H.D., Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 285:11 (2001), 1489–1499.
64. [64] Craig, M.C., Maki, P.M., Murphy, D.G., The women's health initiative memory study: findings and implications for treatment. Lancet Neurol. 4:3 (2005), 190–194.
65. [65] Shumaker, S.A., Legault, C., Kuller, L., Rapp, S.R., Thal, L., Lane, D.S., et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: women's Health Initiative Memory Study. JAMA 291:24 (2004), 2947–2958.
66. [66] Grady, D., Yaffe, K., Kristof, M., Lin, F., Richards, C., Barrett-Connor, E., Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. Am. J. Med. 113:7 (2002), 543–548.
67. [67] Mulnard, R.A., Cotman, C.W., Kawas, C., van Dyck, C.H., Sano, M., Doody, R., et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial Alzheimer's Disease Cooperative Study. JAMA 283:8 (2000), 1007–1015.
68. [68] Hogervorst, E., Bandelow, S., Sex steroids to maintain cognitive function in women after the menopause: a meta-analyses of treatment trials. Maturitas 66:1 (2010), 56–71.
69. [69] O'Brien, J., Jackson, J.W., Grodstein, F., Blacker, D., Weuve, J., Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer's disease. Epidemiol. Rev. 36 (2014), 83–103.
70. [70] Depypere, H.T., Tummers, P., De Bacquer, D., De Backer, G., Do, M., Dhont, M., Number of women needed in a prospective trial to prove potential cardiovascular benefit of hormone replacement therapy. Climacteric 10:3 (2007), 238–243.
71. [71] Xing, D., Nozell, S., Chen, Y.F., Hage, F., Oparil, S., Estrogen and mechanisms of vascular protection. Arterioscler. Thromb. Vasc. Biol. 29:3 (2009), 289–295.
72. [72] Henderson, V.W., Benke, K.S., Green, R.C., Cupples, L.A., Farrer, L.A., Group, M.S., Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J. Neurol. Neurosurg. Psychiatry 76:1 (2005), 103–105.
73. [73] Shao, H., Breitner, J.C., Whitmer, R.A., Wang, J., Hayden, K., Wengreen, H., et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology 79:18 (2012), 1846–1852.
74. [74] Whitmer, R.A., Quesenberry, C.P., Zhou, J., Yaffe, K., Timing of hormone therapy and dementia: the critical window theory revisited. Ann. Neurol. 69:1 (2011), 163–169.
75. [75] Gleason, C.E., Dowling, N.M., Wharton, W., Manson, J.E., Miller, V.M., Atwood, C.S., et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-cognitive and affective study. PLoS Med., 12(6), 2015, e1001833 (discussion e).
76. [76] Hodis, H.N., Mack, W.J., Henderson, V.W., Shoupe, D., Budoff, M.J., Hwang-Levine, J., et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N. Engl. J. Med. 374:13 (2016), 1221–1231.
77. [77] Burkhardt, M.S., Foster, J.K., Laws, S.M., Baker, L.D., Craft, S., Gandy, S.E., et al. Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4. J. Alzheimer's Dis.: JAD. 6:3 (2004), 221–228.
78. [78] Yaffe, K., Haan, M., Byers, A., Tangen, C., Kuller, L., Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 54:10 (2000), 1949–1954.
79. [79] Kang, J.H., Grodstein, F., Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. Neurobiol. Aging 33:7 (2012), 1129–1137.
80. [80] Ryan, J., Carriere, I., Scali, J., Dartigues, J.F., Tzourio, C., Poncet, M., et al. Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study. Neurology 73:21 (2009), 1729–1737.
81. [81] Rippon, G.A., Tang, M.X., Lee, J.H., Lantigua, R., Medrano, M., Mayeux, R., Familial Alzheimer disease in Latinos: interaction between APOE, stroke, and estrogen replacement. Neurology 66:1 (2006), 35–40.
82. [82] Yue, Y., Hu, L., Tian, Q.J., Jiang, J.M., Dong, Y.L., Jin, Z.Y., et al. Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes. Acta Pharmacol. Sin. 28:8 (2007), 1129–1135.
83. [83] Sundermann, E.E., Gilbert, P.E., Murphy, C., The effect of hormone therapy on olfactory sensitivity is dependent on apolipoprotein E genotype. Horm. Behav. 54:4 (2008), 528–533.
84. [84] Struble, R.G., Cady, C., Nathan, B.P., McAsey, M., Apolipoprotein E may be a critical factor in hormone therapy neuroprotection. Front. Biosci.: J. Virtual Lib. 13 (2008), 5387–5405.
85. [85] Hofman, A., Ott, A., Breteler, M.M., Bots, M.L., Slooter, A.J., van Harskamp, F., et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349:9046 (1997), 151–154.
86. [86] Newman, A.B., Fitzpatrick, A.L., Lopez, O., Jackson, S., Lyketsos, C., Jagust, W., et al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J. Am. Geriatr. Soc. 53:7 (2005), 1101–1107.
87. [87] van Oijen, M., de Jong, F.J., Witteman, J.C., Hofman, A., Koudstaal, P.J., Breteler, M.M., Atherosclerosis and risk for dementia. Ann. Neurol. 61:5 (2007), 403–410.
88. [88] Wendell, C.R., Waldstein, S.R., Ferrucci, L., O'Brien, R.J., Strait, J.B., Zonderman, A.B., Carotid atherosclerosis and prospective risk of dementia. Stroke: J. Cereb. Circ. 43:12 (2012), 3319–3324.
89. [89] Lehtimaki, T., Dastidar, P., Jokela, H., Koivula, T., Lehtinen, S., Ehnholm, C., et al. Effect of long-term hormone replacement therapy on atherosclerosis progression in postmenopausal women relates to functional apolipoprotein e genotype. J. Clin. Endocrinol. Metab. 87:9 (2002), 4147–4153.
90. [90] Sarrel, P.M., Ovarian hormones and the circulation. Maturitas 12:3 (1990), 287–298.
91. [91] Freudenberger, T., Oppermann, M., Marzoll, A., Heim, H.K., Mayer, P., Kojda, G., et al. Differential effects of medroxyprogesterone acetate on thrombosis and atherosclerosis in mice. Br. J. Pharmacol. 158:8 (2009), 1951–1960.